Abeona Therapeutics Inc. (ABEO)
Company Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa.
The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.
In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015.
Abeona Therapeutics Inc. is headquartered in New York, New York.
| Country | United States |
| IPO Date | Sep 19, 1980 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Dr. Vishwas Seshadri M.B.A., Ph.D. |
Contact Details
Address: 6555 Carnegie Ave, 4th Floor Cleveland, Ohio 44103 United States | |
| Phone | 646-813-4701 |
| Website | abeonatherapeutics.com |
Stock Details
| Ticker Symbol | ABEO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000318306 |
| CUSIP Number | 00289Y107 |
| ISIN Number | US00289Y2063 |
| Employer ID | 83-0221517 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vishwas Seshadri M.B.A., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Brendan M. O'Malley J.D., Ph.D. | Senior Vice President and General Counsel |
| Joseph Walter Vazzano | Chief Financial Officer |
| Brian Kevany Ph.D. | Vice President, Chief Technology Officer and Head of Research |
| Gregory Gin | Vice President of Investor Relations and Corporate Communications |
| Scott Santiamo | Director of Corporate Communications |
| Alison Hardgrove | Vice President of Human Resources |
| Jon Voss | Vice President and Head of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 4, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 27, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Nov 13, 2023 | 8-K | Current Report |
| Oct 18, 2023 | 8-K | Current Report |
| Oct 10, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 8, 2023 | 8-K | Current Report |
| Aug 8, 2023 | 10-Q | Quarterly Report |
| Jul 7, 2023 | 8-K | Current Report |
| Jul 6, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |